FALCO HOLDINGS (4671) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative Q3 results showed revenue growth of only 0.1%, while Operating Income increased +5.4% YoY due to an improvement in the cost ratio. Although the Company achieved both revenue and profit growth, the quality of growth was dependent on earnings improvement. Revenue was ¥327.8B, Operating Income was ¥17.5B, Ordinary Income was ¥19.1B, and Net Income attributable to owners of the parent was ¥14.1B. The gross profit margin improved to 31.7% from 30.8% in the same period of the previous year; however, Net Income included a gain on the sale of investment securities of ¥2.7B, meaning that recurring earnings power should be assessed based on Operating Income and Ordinary Income.

Factors Affecting Results

【Revenue】Revenue was ¥327.8B, essentially flat at +0.1% YoY. By segment, the Clinical Testing Business generated ¥202.0B (61.6% of total, +0.6% YoY), the Dispensing Pharmacy Business generated ¥114.5B (34.9%, ▲2.3% YoY), and the ICT Business generated ¥11.3B (3.4%, +20.0% YoY). Strong growth in the ICT Business partially offset the decline in the Dispensing Pharmacy Business, but its contribution to overall revenue growth was limited.

【Earnings】Operating Income increased to ¥17.5B (+5.4% YoY), while Ordinary Income increased to ¥19.1B (+6.1% YoY). The primary driver of profit growth was gross profit expansion resulting from a 1.1% decrease in cost of sales. Although SG&A expenses increased +2.5% YoY, the improvement in gross profit more than offset the increase. By segment, the Clinical Testing Business grew to ¥13.9B (+14.5% YoY; margin 6.9%), and the ICT Business grew to ¥2.8B (+47.4%; margin 25.1%), while the Dispensing Pharmacy Business declined to ¥4.2B (▲25.5%; margin 3.7%), becoming a factor constraining overall profit growth. Net Income of ¥14.1B (+2.7% YoY) benefited from extraordinary income of ¥2.7B, including a gain on the sale of investment securities of ¥2.7B; consequently, the rate of bottom-line growth was modest relative to Operating Income growth. In conclusion, although the Company achieved revenue and profit growth, revenue growth drivers were limited, and the overall result was led by cost improvements and profit growth in the ICT Business and Clinical Testing Business.

Segment Analysis

The Clinical Testing Business generated revenue of ¥202.0B (+0.6% YoY) and segment profit of ¥13.9B (+14.5%), with a margin of 6.9% (improved from 6.1% in the same period of the previous year). It is the core business, accounting for 66.3% of total segment profit of ¥21.0B. The Dispensing Pharmacy Business generated revenue of ¥114.5B (▲2.3% YoY) and segment profit of ¥4.2B (▲25.5%), with a margin of 3.7% (down from 4.8% in the same period of the previous year), indicating deteriorating profitability. The ICT Business generated revenue of ¥11.3B (+20.0% YoY) and segment profit of ¥2.8B (+47.4%), with a margin of 25.1% (improved from 20.4% in the same period of the previous year), demonstrating the highest growth rate and margin despite its small scale. Adjustments for Company-wide expenses and other items deteriorated to ▲¥3.5B from ▲¥3.2B in the same period of the previous year, absorbing part of the increase in total segment profit.

Key Financial Indicators

【Profitability】The Operating Income margin improved to 5.3% from 5.1% in the same period of the previous year, while the Ordinary Income margin also rose to 5.8% from 5.5%. However, the Net Income margin remained essentially flat at 4.3%, indicating that improvements at the operating level have not fully flowed through to bottom-line earnings. 【Cash Quality】Cash and deposits were ¥93.7B, substantially exceeding interest-bearing debt of ¥11.6B, resulting in a net cash position. 【Investment Efficiency】Annualized ROE was 7.4%, reflecting a balanced capital efficiency profile comprising a Net Income margin of 4.3%, total asset turnover of 1.18x, and financial leverage of 1.47x. 【Financial Soundness】The Equity Ratio was high at 68.1%. Current assets of ¥186.6B significantly exceeded current liabilities of ¥84.9B, indicating a conservative and stable financial foundation.

Cash Flow Analysis

Because detailed data from the statement of cash flows has not been disclosed, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥93.7B, essentially flat from ¥94.2B in the same period of the previous year, indicating that the cash position has been maintained at a stable level. Inventories increased significantly by +48.9% YoY, while accounts payable also increased to ¥51.8B, suggesting that working capital investment may be progressing in line with business expansion. Property, plant and equipment increased to ¥114.9B, and investment securities also increased to ¥39.1B, indicating continued allocation of funds to capital investment and financial assets. Interest-bearing debt was limited to ¥11.6B; given the combination of abundant cash and low reliance on borrowings, concerns regarding financial liquidity are considered limited.

Quality of Earnings

The increase from Operating Income of ¥17.5B to Ordinary Income of ¥19.1B resulted from non-operating income of ¥1.8B exceeding non-operating expenses of ¥0.1B. Of this amount, dividends received of ¥1.2B represented 6.1% of Ordinary Income and constituted stable financial income. Profit Before Tax of ¥21.8B included extraordinary income of ¥2.7B, primarily consisting of a ¥2.7B gain on the sale of investment securities, while extraordinary losses were limited to ¥0.03B. Accordingly, the divergence between Profit Before Tax and Ordinary Income was approximately 14%, with most of the difference explained by a one-time factor related to asset sales. The Net Income growth rate (+2.7%) of ¥14.1B was below the Operating Income growth rate (+5.4%) partly because the gain on the sale of investment securities decreased to ¥2.7B in the current period from ¥3.3B in the same period of the previous year. Therefore, Operating Income and Ordinary Income should be given greater weight when assessing recurring earnings power. Comprehensive Income was ¥16.6B, exceeding Net Income by ¥2.5B, with an increase in valuation differences on securities contributing to the result.

Earnings Forecasts and Guidance

Cumulative Q3 progress against the full-year Company forecasts was 75.2% for Revenue, 69.8% for Operating Income, 73.5% for Ordinary Income, and 72.3% for Net Income. Revenue progress was consistent with the standard level of 75% at the Q3 stage, while Operating Income progress was 5.2 percentage points below the standard level. To achieve the full-year forecast, the Company needs Revenue of ¥108.3B and Operating Income of ¥7.5B in Q4. This would require an Operating Income margin of approximately 7.0%, exceeding the cumulative actual margin of 5.3%. Maintaining profitability in the Clinical Testing Business, continuing strong growth in the ICT Business, and recovering profitability in the Dispensing Pharmacy Business will be the key factors in achieving the plan in Q4.

Shareholder Returns

The Q2 dividend was ¥62.5 per share, and the full-year forecast for annual dividends is ¥125.0 per share (assuming a year-end dividend of ¥62.5). The forecast Payout Ratio against forecast EPS of ¥192.01 is approximately 65.1%. As dividend-only returns, this remains within the range of earnings, although it is slightly above the general guideline of less than 60%. The financial position of cash and deposits of ¥93.7B and interest-bearing debt of ¥11.6B provides support for continued dividend payments. However, because current-period Net Income includes a gain on the sale of investment securities, it is important to monitor trends in recurring earnings generation when assessing the sustainability of dividend capacity.

Risk Factors

1. Declining profitability in the Dispensing Pharmacy Business: Revenue decreased ▲2.3% YoY, while segment profit declined ▲25.5%, and the margin fell to 3.7% (4.8% in the same period of the previous year). Deteriorating profitability due to drug price revisions, procurement costs, and labor cost trends is weighing on overall Company profit.

2. Earnings dependence on the Clinical Testing Business: The Clinical Testing Business accounts for 66.3% of total segment profit, meaning that changes in testing demand, medical reimbursement revisions, and testing prices have a significant impact on overall Company earnings.

3. Increase in inventories: Inventories increased +48.9% YoY to ¥11.7B. Although inventories represent a limited 3.2% of total assets, inventory turnover and valuation loss risks need to be monitored in conjunction with declining revenue and profit in the Dispensing Pharmacy Business.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (it_telecom)

Profitability and Returns

Both the Operating Income margin and Net Income margin are below the industry median, placing the Company’s profitability somewhat toward the lower end of the industry.

Growth and Capital Efficiency

The Revenue growth rate is significantly below the industry median, and the Company also ranks toward the lower end of the industry in terms of growth.

※Source: Company compilation

Key Earnings Takeaways

1. While Revenue was essentially flat (+0.1%), Operating Income increased +5.4% due to an improvement in the cost ratio. A key characteristic is that the source of profit growth was not top-line growth but improvement in the cost structure.

2. By segment, the Clinical Testing Business and ICT Business led profit growth, while the Dispensing Pharmacy Business recorded double-digit declines in both revenue and profit, widening the profitability gap across the business portfolio.

3. Net Income includes a gain on the sale of investment securities of ¥2.7B. Together with the full-year Operating Income progress rate of 69.8% (below the standard 75%), this makes it useful to distinguish recurring earnings power from one-time gains and losses when interpreting the results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥2,339–¥2,470 at ±1% for the Cost of Equity, and ¥2,399–¥2,405 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used (there is a timing discrepancy relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---